Given the importance of inflammatory and metabolic markers in the pathophysiology of non-
alcoholic fatty liver disease (NAFLD), this study was designed to evaluate the effects of …

What is known and objective Non‐alcoholic fatty liver disease (NAFLD) is the most common
cause of chronic liver injury. Some animal studies suggest that alpha‐lipoic acid (ALA) can …

Considering the importance of adipokines in the pathophysiology of non-alcoholic fatty liver
disease (NAFLD), and due to the possible beneficial effects of α-lipoic acid (α-LA) on these …

Background: Several mechanisms have been suggested to explain the pathogenesis of
nonalcoholic fatty liver disease (NAFLD) and its progression, one of which is increased …

Background: Insulin resistance has a pivotal role in the occurrence of impaired glucose
tolerance and dyslipidemia in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) …

OBJECTIVES: The pharmacologic approach to disease management has not (as of yet)
demonstrated safety and efficacy in nonalcoholic fatty liver disease (NAFLD). The current …

Objective: Antioxidants, including alpha lipoic acid (ALA) and vitamin E, are efficacious for
the treatment of nonalcoholic fatty liver disease (NAFLD). The objective was to evaluate the …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the
Western world. Its prevalence has increased with the growing obesity epidemic, yet no …

Background To compare the effects of α-lipoic acid (ALA), myo-inositol (MI) and propolis
supplementation on metabolic parameters and liver function in obese patients with non …

Aliment Pharmacol Ther 31, 679–692 Summary Background Non‐alcoholic fatty liver
disease affects 10–35% of the adult population worldwide; there is no consensus on its …